» Articles » PMID: 39343571

Clinical Course and Factors Correlated with Severe Morbidity and Mortality in Patients with Coronavirus Disease 2019 Undergoing Maintenance Dialysis in Kanagawa, Japan

Abstract

Objective Patients undergoing maintenance dialysis are at a higher risk of morbidity and mortality due to severe coronavirus disease 2019 (COVID-19) than the general population. However, longitudinal data regarding this subpopulation of patients are lacking. We therefore examined the prognosis of patients with COVID-19 undergoing maintenance dialysis between 2020 and 2023. In addition, we explored the factors correlated with COVID-19 severity, focusing on the transition thereof throughout the observational period. Methods The primary outcome was the progression to severe or fatal COVID-19. We evaluated the correlation between the primary outcome and baseline demographic and clinical characteristics of patients. Patients undergoing maintenance dialysis who were hospitalized for mild-to-moderate COVID-19 between February 2020 and April 2023 were enrolled at four institutions in Kanagawa, Japan. Results Of the 173 patients, 7 (4.0%) developed severe COVID-19, and 12 (6.9%) died. The severe/death cohort was significantly older, with a higher percentage of unvaccinated patients than the non-severe cohort (58.2% and 25.0%, respectively; p=0.016). Thymus and activation-regulated chemokine levels on admission were lower in the severe/death cohort than in the non-severe cohort, albeit not to a statistically significant degree (148±84 mg/dL and 342±657 pg/mL, respectively; p=0.082). A multivariate logistic regression analysis revealed that the odds ratio for severe morbidity or death was 0.23 (95% confidence interval: 0.07-0.75) for vaccinated patients. Conclusion In patients undergoing maintenance dialysis, the severity rate of COVID-19 is approximately 10%. Vaccination was correlated with a reduced risk of severe COVID-19.

References
1.
Kanai D, Wakui H, Haze T, Azushima K, Kinguchi S, Kanaoka T . Improved Immune Response to the Third COVID-19 mRNA Vaccine Dose in Hemodialysis Patients. Kidney Int Rep. 2022; 7(12):2718-2721. PMC: 9464310. DOI: 10.1016/j.ekir.2022.09.005. View

2.
Tsukamoto S, Wakui H, Azushima K, Yamaji T, Urate S, Suzuki T . Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease. Sci Rep. 2021; 11(1):16843. PMC: 8377123. DOI: 10.1038/s41598-021-96294-8. View

3.
Wing S, Thomas D, Balamchi S, Ip J, Naylor K, Dixon S . Effectiveness of Three Doses of mRNA COVID-19 Vaccines in the Hemodialysis Population during the Omicron Period. Clin J Am Soc Nephrol. 2023; 18(4):491-498. PMC: 10103340. DOI: 10.2215/CJN.0000000000000108. View

4.
Feikin D, Higdon M, Abu-Raddad L, Andrews N, Araos R, Goldberg Y . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399(10328):924-944. PMC: 8863502. DOI: 10.1016/S0140-6736(22)00152-0. View

5.
Miyashita K, Hozumi H, Furuhashi K, Nakatani E, Inoue Y, Yasui H . Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study. Emerg Microbes Infect. 2022; 12(1):2155250. PMC: 9788709. DOI: 10.1080/22221751.2022.2155250. View